CEO Executive AssistantDrug safety does not pause between board meetings. For pharmaceutical CEOs, pharmacovigilance is one of the few operational functions where a gap in oversight can create regulatory, legal, and reputational consequences simultaneously. A missed expedited safety report, a delayed signal evaluation, or an uncoordinated response to a safety crisis can trigger FDA enforcement action, product withdrawal, or litigation exposure that no pipeline success can offset.
Pharma CEO pharmacovigilance coordination is not about the CEO becoming a safety scientist. It is about the CEO having the administrative infrastructure to maintain meaningful governance over the safety function: the right information at the right time, the right meetings scheduled and prepared for, and the right reporting structures connecting safety operations to the board. Executive assistant support delivers that infrastructure. This article covers how it works across safety reporting oversight, signal management coordination, regulatory timeline tracking, and cross-functional safety governance.
Why Pharma CEOs Cannot Delegate Pharmacovigilance Oversight Entirely
Pharmacovigilance sits at the intersection of patient safety, regulatory compliance, and commercial viability. The CEO who fully delegates visibility into safety operations is the CEO who learns about a safety crisis from a regulator rather than from their own organization.
The FDA requires pharmaceutical companies to submit Individual Case Safety Reports (ICSRs) for serious and unexpected adverse events within 7 or 15 calendar days of receipt, depending on the event type. The European Medicines Agency has its own expedited reporting timelines under EudraVigilance. A company that routinely misses these deadlines faces warning letters, consent decrees, and in serious cases, product suspensions. These are CEO-level regulatory compliance failures.
Beyond expedited reporting, the pharmacovigilance function manages periodic safety update reports, risk management programs (REMs in the US, RMPs in Europe), labeling updates driven by safety signals, and the continuous signal detection activity that monitors post-market safety data. Each of these threads has its own regulatory timeline, cross-functional dependencies, and CEO-level governance implications.
The EA does not manage any of this operationally. The pharmacovigilance team does. The EA’s role is to build and maintain the coordination infrastructure that gives the CEO consistent, current visibility without requiring the CEO to pull information from the safety team manually.
Safety Reporting Oversight: Building the Coordination System
Expedited Reporting Calendar
The most time-critical element of pharmacovigilance administration is expedited case reporting. Seven-day and 15-day safety reports are regulatory obligations with no flexibility on timing. While the pharmacovigilance team manages these reports operationally, the CEO benefits from a macro-level view of the company’s expedited reporting activity: volumes, trends, and any instances where the 7- or 15-day windows were at risk of being missed.
The EA maintains a monthly safety reporting summary, compiled in coordination with the head of pharmacovigilance, that captures expedited report volumes by product and event type, any near-miss timeline situations, and any significant cases that may require CEO awareness. This summary is not a clinical document; it is a governance tool that tells the CEO whether the safety reporting function is operating within its regulatory requirements.
When a particularly significant expedited report is filed (a cluster of fatal adverse events, a safety signal that may trigger a label change, or a case with litigation implications), the EA ensures the CEO receives a real-time briefing rather than discovering the development in a routine meeting. The EA works with the pharmacovigilance head to define in advance which event types trigger immediate CEO notification versus routine monthly reporting.
Periodic Safety Update Report (PSUR) and PBRER Coordination
Periodic Benefit-Risk Evaluation Reports (PBRERs), known as PSURs in older regulatory frameworks, are comprehensive safety reviews required on a defined schedule for all marketed products: typically annually for the first two years post-approval, then every three years thereafter. For companies with large marketed portfolios, PSUR preparation is a significant organizational effort that runs continuously.
The EA maintains a PSUR/PBRER calendar that tracks the submission due date for every marketed product, the internal preparation milestones (first draft, medical review, regulatory review, CEO/executive sign-off, submission), and the current completion status for each active report. This calendar feeds a standing agenda item in the CEO’s regular safety check-ins, ensuring the CEO has advance visibility into upcoming PSUR submissions and any reports at risk of falling behind schedule.
When a PSUR is approaching executive sign-off, the EA schedules dedicated review time with the CEO and ensures the report and any supporting briefing documents are distributed in advance. PSURs require executive attestation in many regulatory jurisdictions; the EA tracks these sign-off requirements and ensures they are completed within the required windows.
Signal Management and Safety Committee Coordination
The Pharmacovigilance Committee Structure
Most pharmaceutical companies with marketed products operate a formal pharmacovigilance committee or safety review board: a cross-functional body that reviews safety signals, evaluates risk-benefit data, and makes recommendations on labeling changes, REM modifications, or communications to healthcare providers. The CEO typically does not sit on this committee operationally, but maintains strategic oversight through briefings and escalation protocols.
The EA coordinates the CEO’s interface with the pharmacovigilance committee by maintaining the committee meeting schedule, ensuring the CEO receives a summary of committee decisions and recommendations after each meeting, and coordinating the escalation pathway for decisions that require CEO input or board-level awareness.
For pharma CEOs who want to understand how to structure oversight of multiple regulatory and safety functions simultaneously, regulatory affairs coordination provides frameworks for maintaining CEO-level governance without displacing operational teams.
Signal Detection and Evaluation Workflows
Signal detection is the process by which pharmacovigilance teams identify potential safety concerns in post-market adverse event data. When a signal is detected, it moves through an evaluation process: signal validation, signal analysis, signal assessment, and a benefit-risk evaluation that determines whether regulatory action is warranted.
The CEO needs visibility into significant signals, particularly those that may lead to labeling changes, REM modifications, or communications to the FDA. The EA builds a signal tracking log at the CEO level, updated monthly by the pharmacovigilance team, that captures all active signals under evaluation, the current stage of evaluation, and the anticipated timeline for a recommendation.
This log is not the pharmacovigilance team’s internal signal database; it is a CEO-level governance view. When a signal advances to the assessment stage or triggers a recommendation for regulatory action, the EA flags it for CEO review and coordinates the briefing meeting with the chief medical officer and pharmacovigilance leadership.
Crisis-Level Safety Event Coordination
When a safety event reaches crisis level (a cluster of unexpected fatalities, a signal suggesting a serious class effect, or an FDA-initiated safety inquiry), the CEO’s response requirements change dramatically. The CEO must be briefed immediately, the board must be notified, legal must be engaged, and communications to regulators, healthcare providers, and potentially the public must be coordinated under extreme time pressure.
The EA’s role in a safety crisis is to ensure the CEO’s coordination infrastructure does not become a bottleneck. This means the CEO has immediate access to the pharmacovigilance head and chief medical officer, emergency board notification protocols are in place, and the CEO’s schedule can be cleared rapidly to accommodate crisis management demands. The EA maintains a crisis coordination protocol, reviewed and updated annually, that defines these escalation pathways before they are needed.
Regulatory Timeline Tracking for Pharmacovigilance
FDA and International Safety Submissions
Pharmacovigilance regulatory submissions extend well beyond expedited case reports. Post-marketing safety commitments, post-marketing required studies, Risk Evaluation and Mitigation Strategy (REMS) assessments, and label update submissions triggered by safety signals all have regulatory deadlines that require tracking.
The FDA’s pharmacovigilance requirements establish the framework for post-market safety reporting in the US, with international submissions governed by ICH E2 guidelines and individual market authority requirements. The EA maintains a cross-regulatory submission calendar that captures all active pharmacovigilance submission obligations, their due dates, and current completion status.
This calendar is reviewed monthly with the pharmacovigilance and regulatory teams and serves as a standing agenda item in the CEO’s quarterly safety governance review. When deadlines shift, when new post-marketing commitments are accepted in an approval letter, or when a safety-driven label update generates a new submission obligation, the EA updates the calendar and flags any changes to the CEO.
REMS Program Oversight
For products with approved REMS programs (restricted distribution systems, medication guides, elements to assure safe use), the ongoing program management obligations are significant. REMS assessments are required at defined intervals (18 months, 3 years, 7 years post-approval for most programs), and the FDA can request modifications to REMS programs at any time based on emerging safety data.
The EA maintains a REMS oversight tracker that captures the current REMS program requirements for each affected product, the next scheduled assessment date, and the current status of any FDA-requested modifications. When a REMS assessment is approaching, the EA coordinates the executive review process and ensures the CEO receives a briefing on the assessment findings before the document is submitted to the FDA.
Cross-Functional Safety Governance
The Pharmacovigilance-Regulatory Interface
Pharmacovigilance and regulatory affairs are closely linked functions: safety data drives labeling decisions, signal evaluations trigger FDA communications, and expedited safety reports feed into the company’s regulatory relationship. The CEO’s coordination of these two functions requires visibility into both calendars simultaneously.
The EA maintains a joint safety-regulatory calendar that captures the intersections: label update submissions driven by safety signals, FDA meeting requests triggered by safety concerns, REMS modification negotiations, and post-marketing commitment fulfillment linked to safety data generation. This joint calendar is reviewed in the CEO’s combined safety-regulatory check-in, typically held quarterly or more frequently when active safety issues require it.
For programs in active clinical development, pharmacovigilance intersects with clinical operations as well. Clinical trial coordination covers how to structure the CEO’s oversight of safety data in the clinical development context, including DSMB oversight and SAE notification protocols.
Medical Affairs and Pharmacovigilance Alignment
When safety signals lead to healthcare provider communications, labeling updates, or risk management program changes, the medical affairs team is a critical execution partner for pharmacovigilance. The EA coordinates the CEO’s involvement in cross-functional safety-medical affairs alignment: scheduling the relevant alignment meetings, ensuring the CEO receives briefings when healthcare provider communications are being finalized, and tracking the deployment of any physician or patient communications through the medical affairs organization.
These cross-functional coordination points are where safety information most commonly stalls or gets lost between organizational silos. The EA’s coordination role at the CEO level ensures these hand-offs happen cleanly and that the CEO has visibility when they do not.
Board-Level Pharmacovigilance Reporting
The board of directors has a governance obligation to understand the company’s pharmacovigilance posture: whether safety reporting obligations are being met, whether significant safety signals exist across the portfolio, and whether any products face regulatory action driven by safety concerns. Translating this information into board-appropriate narrative requires collaboration between the pharmacovigilance team, the chief medical officer, and the CEO’s office.
The EA coordinates the pharmacovigilance component of board reporting by working with pharmacovigilance leadership to compile the safety section of quarterly board materials. This section typically covers: expedited reporting compliance summary, active signal evaluations and their current status, REMS program status for applicable products, any significant FDA safety communications received or anticipated, and post-marketing commitment completion status.
The EA ensures this section is reviewed by the CEO before the board packet is finalized, that the language is accessible to non-scientist directors, and that any items requiring board-level decision or awareness are clearly flagged. When safety developments are material to investors, the EA coordinates with the legal and investor relations teams to ensure disclosure obligations are met.
Building the Pharmacovigilance Oversight Infrastructure
The CEO Safety Dashboard
The most effective pharma CEO pharmacovigilance coordination systems converge on a single, recurring dashboard: a one-to-two page document that gives the CEO a current view of the entire safety function across all marketed products and active development programs. This dashboard covers expedited reporting compliance, active safety signals, upcoming PSUR submissions, REMS program status, and any pending FDA safety inquiries.
The EA builds and maintains this dashboard in collaboration with the pharmacovigilance and regulatory teams, updating it before each monthly safety check-in. The dashboard format evolves over time to reflect the specific safety profile of the company’s portfolio and the CEO’s most important oversight priorities. A well-designed safety dashboard turns pharmacovigilance oversight from a time-consuming information-gathering exercise into a five-minute governance review.
Integrating Safety Timelines with Portfolio Strategy
Safety developments can have direct consequences for pipeline strategy: a safety signal in a class can affect development decisions for compounds with the same mechanism of action, a REMS program adds complexity and cost to commercial launch planning, and a label restriction driven by safety data can narrow the commercial opportunity for a product. The CEO’s strategic decision-making on the portfolio requires safety information to be integrated into the portfolio planning context.
The EA supports this integration by ensuring the safety dashboard is reviewed in the same cadence as portfolio strategy discussions, and that significant safety developments are immediately communicated to the commercial and clinical development teams. The CEO should not be the sole conduit between the safety function and the rest of the organization; the EA’s coordination role makes safety information flow systematically rather than waiting for the CEO to relay it.
Conclusion
Pharma CEO pharmacovigilance coordination is one of the highest-stakes oversight responsibilities in the pharmaceutical industry. A CEO with strong administrative infrastructure around the safety function can maintain meaningful governance over expedited reporting compliance, signal management, regulatory timelines, and board-level safety reporting without displacing the pharmacovigilance team’s operational focus. An EA who builds and maintains that infrastructure, including the safety dashboard, the submission calendar, the signal tracking log, and the cross-functional coordination protocols, gives the CEO the visibility to lead proactively rather than respond reactively. In an industry where safety failures are existential, that distinction is not academic.